心房分流装置治疗射血分数保留和轻度降低的心力衰竭(REDUCE LAP-HF II):一项随机、多中心、盲法、假手术对照试验
REDUCE LAP-HF II是一项在89个中心进行的随机、双盲、假手术对照试验,纳入626例有症状、射血分数≥40%、运动时肺毛细血管楔压≥25 mmHg且超过右房压≥5 mmHg的心力衰竭患者,1:1随机接受心房分流装置(n=314)或假手术(n=312)。主要终点为12个月心血管死亡或非致死性缺血性卒中、24个月内心力衰竭事件总发生率、12个月堪萨斯城心肌病问卷总分变化的层次复合终点,两组无差异(胜率1.0,95%CI 0.8-1.2;p=0.85),各单独组分也无差异。预设亚组分析显示,运动20W时肺动脉收缩压(交互p=0.002,>70 mmHg与更差结局相关)、右房容积指数(交互p=0.012,≥29.7 mL/m2与更差结局相关)和性别(交互p=0.02,男性与更差结局相关)对心力衰竭事件存在差异效应。复合安全终点两组无差异(装置组116例[38%] vs 假手术组97例[31%];p=0.11)。作者结论认为,在整体人群中,心房分流装置未减少心力衰竭事件总发生率或改善健康状况。
要点
- 在射血分数≥40%的心力衰竭患者中,心房分流装置与假手术相比,主要复合终点无差异(胜率1.0,95%CI 0.8-1.2;p=0.85)。
- 主要终点的各单独组分(12个月心血管死亡或非致死性缺血性卒中、24个月心力衰竭事件总发生率、12个月KCCQ总分变化)两组均无差异。
- 预设亚组中,运动20W时肺动脉收缩压>70 mmHg者(交互p=0.002)、右房容积指数≥29.7 mL/m2者(交互p=0.012)、男性(交互p=0.02)接受心房分流装置后心力衰竭事件结局更差。
- 复合安全终点两组无差异:装置组116例(38%)vs 假手术组97例(31%);p=0.11。
- 作者结论:在射血分数≥40%的心力衰竭整体人群中,心房分流装置未减少心力衰竭事件总发生率或改善健康状况。
适用人群与场景
- 年龄≥40岁、有症状的心力衰竭、射血分数≥40%、运动时肺毛细血管楔压≥25 mmHg且超过右房压≥5 mmHg的患者。
- 研究在89个医疗中心进行,纳入随机分配并接受治疗的患者(改良意向治疗人群),排除随机分配后发现不符合条件而未治疗者。
诊断标准与关键阈值
- 入选标准:有症状心力衰竭,射血分数≥40%,运动时肺毛细血管楔压≥25 mmHg且超过右房压≥5 mmHg。
处置流程与药物剂量
- 患者1:1随机接受心房分流装置或假手术,患者与结局评估者设盲。
研究设计与关键结果
- 研究类型:随机、国际、盲法、假手术对照试验,在89个医疗中心进行;2017年5月25日至2020年7月24日纳入1072例,其中626例随机分配至心房分流装置组(n=314)或假手术组(n=312)。
- 主要终点为12个月心血管死亡或非致死性缺血性卒中、24个月内心力衰竭事件总发生率、12个月堪萨斯城心肌病问卷总分变化的层次复合终点;两组无差异(胜率1.0,95%CI 0.8-1.2;p=0.85),各单独组分也无差异。
- 预设亚组分析显示,运动20W时肺动脉收缩压对心房分流装置疗效存在交互作用(交互p=0.002),>70 mmHg与更差结局相关。
- 预设亚组分析显示,右房容积指数对心房分流装置疗效存在交互作用(交互p=0.012),≥29.7 mL/m2与更差结局相关。
- 预设亚组分析显示,性别对心房分流装置疗效存在交互作用(交互p=0.02),男性与更差结局相关。
- 复合安全终点:装置组116例(38%)vs 假手术组97例(31%);p=0.11,两组无差异。
证据类型、等级与局限
- 证据类型:随机、多中心、盲法、假手术对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在射血分数≥40%的心力衰竭整体人群中,心房分流装置未减少心力衰竭事件总发生率或改善健康状况(胜率1.0,95%CI 0.8-1.2;p=0.85)。
- 预设亚组提示,运动20W时肺动脉收缩压>70 mmHg、右房容积指数≥29.7 mL/m2或男性患者接受心房分流装置后心力衰竭事件结局更差(交互p分别为0.002、0.012、0.02)。
指南或共识出处
- REDUCE LAP-HF II试验,注册号ClinicalTrials.gov NCT03088033,资助方Corvia Medical。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Placement of an interatrial shunt device reduces pulmonary capillary wedge pressure during exercise in patients with heart failure and preserved or mildly reduced ejection fraction. We aimed to investigate whether an interatrial shunt can reduce heart failure events or improve health status in these patients.
METHODS: In this randomised, international, blinded, sham-controlled trial performed at 89 health-care centres, we included patients (aged ≥40 years) with symptomatic heart failure, an ejection fraction of at least 40%, and pulmonary capillary wedge pressure during exercise of at least 25 mm Hg while exceeding right atrial pressure by at least 5 mm Hg. Patients were randomly assigned (1:1) to receive either a shunt device or sham procedure. Patients and outcome assessors were masked to randomisation. The primary endpoint was a hierarchical composite of cardiovascular death or non-fatal ischemic stroke at 12 months, rate of total heart failure events up to 24 months, and change in Kansas City Cardiomyopathy Questionnaire overall summary score at 12 months. Pre-specified subgroup analyses were conducted for the heart failure event endpoint. Analysis of the primary endpoint, all other efficacy endpoints, and safety endpoints was conducted in the modified intention-to-treat population, defined as all patients randomly allocated to receive treatment, excluding those found to be ineligible after randomisation and therefore not treated. This study is registered with ClinicalTrials.gov, NCT03088033.
FINDINGS: Between May 25, 2017, and July 24, 2020, 1072 participants were enrolled, of whom 626 were randomly assigned to either the atrial shunt device (n=314) or sham procedure (n=312). There were no differences between groups in the primary composite endpoint (win ratio 1·0 [95% CI 0·8-1·2]; p=0·85) or in the individual components of the primary endpoint. The prespecified subgroups demonstrating a differential effect of atrial shunt device treatment on heart failure events were pulmonary artery systolic pressure at 20W of exercise (pinteraction=0·002 [>70 mm Hg associated with worse outcomes]), right atrial volume index (pinteraction=0·012 [≥29·7 mL/m2, worse outcomes]), and sex (pinteraction=0·02 [men, worse outcomes]). There were no differences in the composite safety endpoint between the two groups (n=116 [38%] for shunt device vs n=97 [31%] for sham procedure; p=0·11).
INTERPRETATION: Placement of an atrial shunt device did not reduce the total rate of heart failure events or improve health status in the overall population of patients with heart failure and ejection fraction of greater than or equal to 40%.
FUNDING: Corvia Medical.
参考来源
- Shah SJ, Borlaug BA, Chung ES, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet. 2022. PMID: 35120593. doi:10.1016/S0140-6736(22)00016-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。